PainReform new manufacturing process for PRF-110 achieves 18-month stability

PainReform announces a major advancement in the development of its lead asset, PRF-110. The Company’s new highly scalable manufacturing process, for which it recently filed a new patent, has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This stability study is ongoing and marks a significant achievement for PainReform. Ehud Geller, Chairman and interim Chief Executive Officer of PainReform, commented, “Achieving 18-month stability for PRF-110 at room temperature is a major accomplishment for PainReform and a significant validation of our new manufacturing process. This stability not only simplifies logistics and reduces costs but also underscores our commitment to ensuring the highest standards of safety and efficacy for our products. As we look forward to the top-line results from our Phase 3 trial in the second half of 2024, we are confident that this new process will significantly bolster our future commercialization efforts.”